In diabetic patients, which individuals should receive low‑dose aspirin therapy?

Aspirin Therapy in Diabetic Patients

Clear Indications for Aspirin

All diabetic patients with established atherosclerotic cardiovascular disease (ASCVD) should receive aspirin 75–162 mg daily for secondary prevention, where the benefits far outweigh bleeding risks. 1

Secondary Prevention (Strong Recommendation)

Aspirin is definitively indicated for diabetic patients with any of the following:

• History of myocardial infarction 1
• Prior stroke or transient ischemic attack 1
• Peripheral vascular disease or claudication 1
• History of vascular bypass procedure 1
• Documented angina 1

For these patients, use 75–162 mg daily (81 mg is the most common U.S. formulation), and the cardiovascular benefits clearly exceed bleeding risks. 1

---

Primary Prevention: A More Nuanced Decision

When Aspirin MAY Be Considered (Not Routinely Recommended)

For primary prevention in diabetic patients, aspirin is generally NOT recommended even in those at elevated ASCVD risk, as the 12% reduction in cardiovascular events is approximately counterbalanced by a 29% increase in major bleeding. 1, 2

However, aspirin may be considered after comprehensive shared decision-making in diabetic patients who meet ALL of the following criteria: 1

Inclusion Criteria:

• Age ≥50 years (aspirin not recommended for those <50 years due to low baseline risk) 1
• At least one additional major ASCVD risk factor:
  • Family history of premature cardiovascular disease 1
  • Hypertension 1
  • Dyslipidemia 1
  • Current smoking 1
  • Chronic kidney disease or albuminuria 1

Exclusion Criteria (Absolute Contraindications):

• Age >70 years (bleeding risk exceeds benefit) 1
• History of gastrointestinal bleeding or peptic ulcer disease 1, 3
• Aspirin allergy 1, 3
• Active bleeding tendency or coagulopathy 1
• Concurrent anticoagulant therapy 1, 3
• Recent gastrointestinal bleeding 1
• Clinically active hepatic disease 1
• Anemia or chronic kidney disease with high bleeding risk 1
• Concurrent NSAID use 3
• Three or more alcoholic drinks daily 3

---

Critical Evidence Context

The ASCEND Trial Changed Practice

The landmark ASCEND trial (15,480 diabetic patients, mean follow-up 7.4 years) demonstrated that aspirin reduced serious vascular events by 12% (8.5% vs 9.6%), but increased major bleeding by 29% (4.1% vs 3.2%), with most excess being gastrointestinal bleeding. 1, 2 The absolute number of cardiovascular events prevented was roughly equal to the number of major bleeding episodes induced. 1

Real-World Bleeding Risk

Aspirin increases major bleeding by approximately 5 events per 1,000 patients per year in real-world settings, predominantly gastrointestinal bleeding. 1 This risk is substantially higher in patients >70 years, those with uncontrolled hypertension, or concurrent anticoagulation/NSAID use. 1

No Mortality Benefit in Primary Prevention

Aspirin has shown little to no effect on cardiovascular mortality or all-cause mortality in primary prevention (relative risk ≈0.95), with benefits limited mainly to reduction in non-fatal myocardial infarction. 1

---

Practical Dosing Recommendations

Use 75–162 mg daily; the 81-mg tablet is most common in the U.S. 1

The ADAPTABLE trial demonstrated no significant difference in cardiovascular events or major bleeding between 81 mg and 325 mg daily in patients with established cardiovascular disease (38% had diabetes), supporting use of the lower dose to minimize side effects. 1

---

Special Populations

Aspirin Alternatives

For diabetic patients with documented aspirin allergy and established ASCVD, clopidogrel 75 mg daily should be substituted. 1

Age <21 Years

Aspirin is contraindicated in patients under age 21 due to risk of Reye's syndrome. 1 Patients under age 30 have generally not been studied. 1

Type 1 Diabetes

The same recommendations apply, though evidence is weaker (Grade C recommendation for primary prevention in type 1 diabetes vs. Grade A for type 2 diabetes). 1

---

Common Pitfalls to Avoid

1. Do not prescribe aspirin for primary prevention in diabetic patients >70 years—bleeding risk clearly exceeds benefit in this age group. 1

2. Do not use aspirin as primary prevention in low-risk diabetic patients <50 years without additional risk factors—the minimal cardiovascular benefit is outweighed by bleeding risk. 1

3. Always screen for bleeding risk factors before initiating aspirin—history of GI bleeding, concurrent anticoagulation, NSAID use, or anemia are critical contraindications. 1, 3

4. Prioritize statin therapy, blood pressure control, and lifestyle modification over aspirin—these interventions have stronger evidence for ASCVD risk reduction in diabetic patients. 1

5. Engage in shared decision-making for primary prevention—emphasize that aspirin's benefit (preventing non-fatal MI) is approximately equal to its harm (causing major bleeding). 1